Current Hepatitis Reports

, Volume 12, Issue 3, pp 181–187 | Cite as

Nucleos(t)ide Analogues Therapy for Chronic Hepatitis B in Taiwan: Short-Term Versus Long-Term

  • Cheng-Yuan PengEmail author
Global Perspectives: Taiwan and Asia (ML Yu and RN Chien, Section Editors)


Chronic hepatitis B (CHB) remains an important health issue in Taiwan. The major candidates for antiviral therapy are HBeAg-positive and -negative CHB patients, and individuals with compensated or decompensated cirrhosis. Lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate (TDF) are the currently available nucleos(t)ide analogues (NA). Entecavir and TDF are recommended as the first-line agents for long-term use. The therapeutic endpoints recommended by the Asian Pacific Association for the Study of the Liver treatment guidelines have been adopted for clinical practice. Only a small number of patients qualify for short-term NA therapy; the majority of patients need long-term treatment. Current therapeutic endpoints confer off-therapy durability in approximately 50 % of patients. Patients with cirrhosis should receive long-term NA therapy. The use of serum HBsAg level as a guide for cessation of NA therapy requires further investigation.


Adefovir dipivoxil Chronic hepatitis B Compensated cirrhosis Consolidation therapy Decompensated cirrhosis Entecavir HBeAg-positive HBeAg-negative HBeAg seroconversion HBsAg HBV DNA Hepatitis B virus Hepatocellular carcinoma Lamivudine Nucleos(t)ide analogue Telbivudine Tenofovir disoproxil fumarate 


Conflict of Interest

Cheng-Yuan Peng is a paid board member for Bristol-Myers-Squibb.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ni YH, Chang MH, Wu JF, et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012;57:730–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106:148–55.PubMedCrossRefGoogle Scholar
  3. 3.
    Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis. 2007;27:152–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18:246–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat. 2007;14:147–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int. 2007;1:311–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133:1458–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.PubMedCrossRefGoogle Scholar
  12. 12.
    Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86.PubMedCrossRefGoogle Scholar
  13. 13.
    •• Tseng TC, Liu CJ, Yang HC, et al.: High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142:1140–1149. Sex, age, HBeAg status, HBV genotype, and levels of ALT and HBV DNA were determinants of hepatocellular carcinoma (HCC) risk. Among HBeAg-negative patients with baseline HBV DNA <2,000 IU/mL, age, ALT level ≥40 U/L, and HBsAg level ≥1,000 IU/mL were determinants of HCC risk. Google Scholar
  14. 14.
    •• Tseng TC, Liu CJ, Yang HC, et al.: Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441–450. In genotype B or C infected patients with baseline HBV DNA <2,000 IU/mL, HBsAg level ≥1,000 IU/mL was associated with a higher risk of HBeAg-negative hepatitis, hepatitis flare, and development of cirrhosis during a mean follow-up of 13 years. Google Scholar
  15. 15.
    Chen YC, Chu CM, Yeh CT, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1:267–73.PubMedCrossRefGoogle Scholar
  16. 16.
    Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26:142–52.PubMedCrossRefGoogle Scholar
  17. 17.
    • Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. J Hepatol. 2012;57:442–450. This is an extensive review on the natural history of chronic hepatitis B after the development of cirrhosis and the recent advances in treatment with oral antiviral agents. Google Scholar
  18. 18.
    •• Liaw YF, Kao JH, Piratvisuth T, et al.: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561. This is an updated version of the APASL consensus statement on the general management, indications for fibrosis assessment, time to start or stop therapy, choice of first-line therapy, on- and off-therapy monitoring of patients with chronic hepatitis B, and therapy of patients in special circumstances. Google Scholar
  19. 19.
    European Association for the Study of the Liver. EASL Clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.Google Scholar
  20. 20.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.PubMedCrossRefGoogle Scholar
  21. 21.
    Marcellin P, Buti M, Gane EJ, et al. Six years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology. 2012;56:374A–5A.CrossRefGoogle Scholar
  22. 22.
    Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143:963–73.PubMedCrossRefGoogle Scholar
  23. 23.
    Chotiyaputta W, Peterson C, Ditah FA, et al. Persistence and adherence to nucleos(t)ide treatment for chronic hepatitis B. J Hepatol. 2011;54:12–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology. 1999;30:770–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Chien RN, Liaw YF. Short-term lamivudine therapy in patients with chronic hepatitis B. Intervirology. 2003;46:362–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Tseng TC, Liu CJ, Wang CC, et al. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int. 2008;28:1034–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Peng CY, Chen CB, Lai HC, et al. Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. Hepatol Int. 2011;5:586–96.CrossRefGoogle Scholar
  28. 28.
    Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–73.PubMedCrossRefGoogle Scholar
  29. 29.
    Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Yeh CT, Hsu CW, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol. 2009;45:114–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Kuo YH, Chen CH, Wang JH, et al. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45:75–81.PubMedCrossRefGoogle Scholar
  33. 33.
    • Lee HW, Lee HJ, Hwang JS, et al.: Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010;51:415–421. In 178 HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy for a mean duration of 26 months, 77.5% of patients had sustained virological response at 6 months off therapy. Age ≤40 years and consolidation therapy ≥12 months after HBeAg clearance or seroconversion were independent factors for sustained virological response. Google Scholar
  34. 34.
    Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol. 2009;104:1940–6.PubMedCrossRefGoogle Scholar
  35. 35.
    • Chan HL, Thompson A, Martinot-Peignoux M, et al.: Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report. J Hepatol. 2011; 55:1121–1131. This is a review of the recent advances in the use of serum HBsAg quantitation in the understanding of the natural history and in the assessment of treatment response. Google Scholar
  36. 36.
    Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol. 2010;48:22–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Chien RN, Liaw YF. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. Antivir Ther. 2006;11:947–52.PubMedGoogle Scholar
  38. 38.
    Liu F, Wang L, Li XY, et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol. 2011;26:456–60.PubMedCrossRefGoogle Scholar
  39. 39.
    • Jeng WJ, Sheen IS, Chen YC, et al.: Off therapy durability in chronic hepatitis B e antigen negative patients treated with entecavir. Hepatology 2011;54:1014A-1014A. In 62 HBeAg-negative patients who received entecavir therapy for a mean duration of 735 days and stopped therapy according to the APASL treatment guidelines, 53.2% of patients relapsed at 12 months off therapy. Pre-treatment HBV DNA <2 x 10 5 IU/mL was the only independent predictor of sustained virological response. Google Scholar
  40. 40.
    • Jeng WJ, Sheen IS, Chien RN, et al.: Consolidation duration influences the relapse rate post entecavir treatment in HBeAg negative non-cirrhotic patients with chronic hepatitis B. Hepatol Int. 2012;6:105. In 58 non-cirrhotic patients who achieved undetectable HBV DNA levels with entecavir therapy and stopped therapy according to the APASL treatment guidelines, a consolidation period of >64 weeks versus <64 weeks was associated with relapse rates of 25% and 67%, respectively. Google Scholar
  41. 41.
    • Chan HL, Wong GL, Chim AM, et al.: Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther. 2011;16:1249–1257. In 53 HBeAg-negative chronic hepatitis B patients who received lamivudine for a mean duration of 34 months and a mean post-treatment follow-up of 47 months, 17% of patients achieved a sustained response at 12 months off therapy. HBsAg ≤2 log IU/ml and reduction by >1 log from baseline at the end of treatment had sensitivity, specificity, positive and negative predictive values for sustained response of 78%, 96%, 78% and 96%, respectively. Google Scholar
  42. 42.
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.PubMedCrossRefGoogle Scholar
  43. 43.
    •• Wong GL, Chan HL, Mak CH, et al.: Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013. doi:  10.1002/hep.26301. Entecavir therapy significantly reduced the 5-year cumulative incidence of hepatic events, development of HCC, and liver-related mortality in cirrhotic patients compared to a historic control group. Cirrhotic patients who failed to achieve undetectable HBV DNA levels during entecavir therapy had a comparable risk of hepatic events as the control group.
  44. 44.
    Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002;123:719–27.PubMedCrossRefGoogle Scholar
  45. 45.
    Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol. 2010;53:118–25.PubMedCrossRefGoogle Scholar
  46. 46.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011;60:1109–16.PubMedCrossRefGoogle Scholar
  47. 47.
    •• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al.: Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91–100. Entecavir showed superior virological and biochemical efficacy to adefovir in patients with HBV-related decompensated cirrhosis. Both agents showed comparable clinical benefits and safety profiles after 48 weeks of therapy. Google Scholar
  48. 48.
    • Liaw YF, Sheen IS, Lee CM, et al.: Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62–72. TDF, emtricitabine/TDF, and entecavir were all well-tolerated in patients with HBV-related decompensated liver disease with improvements in virological, biochemical, and clinical parameters after 48 weeks of therapy. Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.School of MedicineChina Medical UniversityTaichungTaiwan
  2. 2.Division of Hepatogastroenterology, Department of Internal MedicineChina Medical University HospitalTaichungTaiwan

Personalised recommendations